Few nutrition questions divide the longevity conversation as sharply as protein. On one side, the fitness world insists you need a gram per pound of body weight — possibly more — to build and keep muscle. On the other, a strand of geroscience warns that high protein drives the very growth-signalling pathways (IGF-1, mTOR) that accelerate ageing in laboratory animals. Both camps cite real data. Neither tells the whole story, and we are not aware of any randomised controlled trial showing that a specific protein target extends human lifespan. That is the honest gap at the centre of this debate.
This article walks through the evidence on both sides, rates the strength of each claim, and explains why the answer almost certainly depends on your age, your activity level, and what else is happening in your body — including, for a growing number of people, a GLP-1 medication.
The case for more protein as you age
The strongest argument for higher protein intake in later life is simple: muscle loss is dangerous, and protein helps preserve muscle.
Sarcopenia — the progressive loss of muscle mass and function — is now recognised as a predictor of mortality in its own right. A systematic review and meta-analysis of observational studies found that sarcopenia was associated with a significantly higher risk of all-cause mortality among community-dwelling older adults. Muscle is not just for athletes; it underpins functional independence, and its loss is associated with higher mortality.
The problem is that the current Recommended Dietary Allowance (RDA) for protein — 0.8 g per kilogram of body weight per day — was set to prevent deficiency, not to optimise health in older adults. The PROT-AGE Study Group, a multinational expert panel, reviewed the evidence and concluded that healthy older people (over 65) need at least 1.0–1.2 g/kg/day to help maintain lean body mass and function, with higher intakes (1.2–1.5 g/kg/day) recommended for those with acute or chronic illness.
When paired with resistance training, higher protein intake does augment muscle gains. A large meta-analysis of 49 randomised controlled trials (1,863 participants) found that protein supplementation during prolonged resistance training significantly increased fat-free mass and strength compared with placebo. The meta-regression identified a breakpoint of roughly 1.6 g/kg/day, beyond which additional protein produced no further detectable benefit. That ceiling matters — it suggests that the "more is always better" mantra has an evidence-based limit, and the limit is well below the 2.2 g/kg (≈1 g/lb) often promoted online.
Evidence strength: STRONG that older adults benefit from protein above the RDA, especially alongside resistance training. The sarcopenia-mortality link is robust. The gap: no RCT shows that any protein target extends human lifespan.
The case for caution: IGF-1, mTOR, and the growth trade-off
Ageing researchers who urge restraint are not ignoring the muscle data. They are pointing to a different body of evidence: the nutrient-sensing pathways.
Levine and colleagues found that higher protein intake was associated with both elevated serum IGF-1 and increased cancer and overall mortality in adults aged 50–65. They proposed that the IGF-1/mTOR nutrient-sensing axis — which is involved in growth and cell proliferation — may mediate the observed link between dietary protein and mortality risk, noting that controlling for IGF-1 attenuated the protein–mortality association.
The most-cited human study on this tension analysed over 6,000 US adults aged 50 and above from the NHANES III cohort. Among those aged 50–65, respondents reporting high protein intake (≥20% of energy) had a 75% higher risk of overall mortality and a fourfold higher risk of cancer death over the following 18 years, associations that the authors linked to differences in serum IGF-1 levels. But in adults over 65, the relationship reversed: high protein was associated with lower cancer and overall mortality.
That age-dependent flip is the crux of the trade-off. In middle age, when growth signalling is high and cancer surveillance matters most, heavy protein loading may carry a cost. In later life, when sarcopenia, frailty, and undernutrition become the dominant threats, the balance tips firmly toward more protein. The study was observational and cannot prove causation — dietary recall is imprecise, and residual confounding is inevitable — but the biological plausibility through the IGF-1/mTOR axis gives the finding weight.
Evidence strength: EMERGING for the human relevance of the mTOR/IGF-1 trade-off. The observational human data is suggestive and the proposed mechanism is biologically plausible, but we are not aware of an interventional trial showing that restricting protein in midlife reduces mortality. The honest position: this is a credible hypothesis, not yet a proven recommendation.
What the dose-response data actually shows
A systematic review and dose-response meta-analysis published in the BMJ pooled 32 prospective cohort studies covering 715,128 participants and 113,039 deaths. Total protein intake was associated with a lower risk of all-cause mortality, and the association was stronger for plant-derived protein: each additional 3% of energy from plant protein per day was linked to a 5% lower risk of death from any cause.
Two things stand out. First, higher total protein intake is consistently associated with lower all-cause mortality at the population level — the IGF-1 concern does not erase that association in pooled data. Second, the source of protein matters: plant protein shows a stronger protective association with mortality than animal protein across multiple analyses. This does not mean animal protein is harmful in absolute terms — the meta-analysis found no significant increase in all-cause mortality with higher animal protein — but it does suggest that how you reach your target matters, not just the number.
The GLP-1 wrinkle: why the question is urgent now
The rise of GLP-1 receptor agonists (semaglutide, tirzepatide) has sharpened the protein debate. In the STEP 1 trial, semaglutide 2.4 mg produced a mean weight loss of roughly 15% over 68 weeks. A narrative review of the GLP-1 literature noted that body-composition analyses across multiple trials consistently show lean body mass decreasing alongside fat mass. That review found that lean mass can account for a substantial proportion of total weight lost, depending on the study and the population.
This creates a practical collision. The very people who stand to gain the most metabolically from GLP-1-mediated weight loss — those with obesity, insulin resistance, elevated HbA1c — are also the ones who can least afford to lose functional muscle. The PROT-AGE threshold of at least 1.0–1.2 g/kg/day, ideally combined with resistance training, is increasingly cited as a plausible strategy to help mitigate lean-mass loss during GLP-1 therapy, though this has not yet been tested in a dedicated RCT with hard outcomes. Omniwo's earlier article on GLP-1 drugs and longevity explores the broader evidence.
Evidence strength: EMERGING. The lean-mass concern is real and measurable; the protein-as-mitigation strategy is biologically plausible and recommended by expert opinion, but has not yet been validated in a dedicated RCT with hard outcomes.
The kidney-load question
A persistent concern is that high protein intake stresses the kidneys. The mechanism is straightforward: protein metabolism produces nitrogenous waste that the kidneys must clear, and higher intakes do raise glomerular filtration rate (a phenomenon called hyperfiltration). The question is whether this adaptive increase causes harm over time.
For people with existing chronic kidney disease (CKD), clinicians typically recommend limiting protein intake — if this applies to you, your GP or specialist will advise. The question here is about people with healthy kidneys.
A systematic review and meta-analysis of 28 controlled studies (1,358 participants without CKD) found that higher-protein diets did not produce clinically meaningful changes in kidney function compared with normal- or lower-protein diets. Glomerular filtration rate rose, as expected, but there was no evidence of progressive kidney damage. The important caveat: most included studies were relatively short (weeks to months), relied on creatinine-based estimates of kidney function (which are themselves influenced by protein intake and muscle mass), and enrolled relatively young, healthy participants. The long-term renal implications of sustained high protein intake over years or decades remain genuinely uncertain.
Evidence strength: MIXED. Short-to-medium-term RCT data in healthy adults is reassuring; long-term data is lacking, and the creatinine-measurement confound means the evidence base is less clean than it looks. For anyone with existing kidney disease or risk factors, protein decisions are clinician-gated.
Pulling the threads together
Here is what the evidence, taken as a whole, supports:
- Expert groups recommend that older adults (roughly 65+) consume more protein than the current RDA — at least 1.0–1.2 g/kg/day, and potentially more if exercising or dealing with acute or chronic illness. For those on a GLP-1 medication that accelerates weight loss, the lean-mass concern strengthens the rationale for adequate protein, though dedicated RCTs are still needed.
- The IGF-1/mTOR concern is biologically real but has not been tested interventionally in humans. The observational data suggests the trade-off is age-dependent: the growth cost of high protein may matter more in midlife than in later life.
- Plant protein sources carry a stronger protective association with mortality than animal sources in large cohort data, though both can be part of a healthy pattern.
- We are not aware of any RCT that has shown a specific protein target extends human lifespan. The recommendations above are extrapolated from surrogate endpoints (muscle mass, strength, IGF-1 levels, mortality risk in observational cohorts), not from a trial that randomised people to different protein intakes and followed them for decades. Such a trial may never be feasible.
- Kidney function is worth understanding in context, particularly for people consuming well above the RDA. If you have concerns about kidney health — especially if you also have diabetes or hypertension — speak to your GP.
The answer to "how much protein for longevity?" is not a single number. It is a function of your age, your training, your metabolic status, and your kidney function — which means it is, at its core, a measurement question.
How Omniwo helps you measure this
Omniwo cannot tell you how much protein to eat — that is a conversation between you, your diet, and your clinician. What it can do is give you a wellness snapshot of kidney-related markers so you and your GP have numbers to discuss.
The Kidney Health Check measures creatinine, estimated glomerular filtration rate (eGFR), and urea — three markers related to kidney function. These results can give you a general wellness snapshot to share with your GP, who can interpret them in the context of your health history. Omniwo does not diagnose or screen for kidney disease — that is your clinician's role.
Worth noting: as the Devries meta-analysis observed, creatinine-based estimates of kidney function can be confounded by factors like protein intake itself and muscle mass — context matters, and a clinician can help you interpret the numbers.
For the broader ageing picture, kidney markers sit alongside HbA1c, lipids, and inflammatory markers in the BioAge composite. Understanding both sides — muscle and kidney — is part of a more complete view of how your body is responding to your choices.
Omniwo's tests and content are for wellness and educational insight. They are not a medical device, do not diagnose, treat, cure or prevent any disease, and do not replace advice from a qualified healthcare professional.
Sources
-
Beaudart C, Zaaria M, Pasleau F, Reginster J-Y, Bruyère O. Sarcopenia as a predictor of all-cause mortality among community-dwelling older people: A systematic review and meta-analysis. Maturitas. 2017;99:20–28. doi:10.1016/j.maturitas.2017.04.003 (PMID: 28778327)
-
Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: A position paper from the PROT-AGE Study Group. Journal of the American Medical Directors Association. 2013;14(8):542–559. doi:10.1016/j.jamda.2013.05.021 (PMID: 23867520)
-
Morton RW, Murphy KT, McKellar SR, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. British Journal of Sports Medicine. 2018;52(6):376–384. doi:10.1136/bjsports-2017-097608 (PMID: 28698222)
-
Levine ME, Suarez JA, Brandhorst S, et al. Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metabolism. 2014;19(3):407–417. doi:10.1016/j.cmet.2014.02.006 (PMID: 24606898)
-
Naghshi S, Sadeghi O, Willett WC, Esmaillzadeh A. Dietary intake of total, animal, and plant proteins and risk of all cause, cardiovascular, and cancer mortality: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ. 2020;370:m2412. doi:10.1136/bmj.m2412 (PMID: 32699048)
-
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 (PMID: 33567185)
-
Neeland IJ, Eliasson B, Engström AE, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. 2024;26(suppl 4):16–27. doi:10.1111/dom.15728 (PMID: 38937282)
-
Devries MC, Sithamparapillai A, Brimble KS, Banfield L, Morton RW, Phillips SM. Changes in kidney function do not differ between healthy adults consuming higher- compared with lower- or normal-protein diets: A systematic review and meta-analysis. Journal of Nutrition. 2018;148(11):1760–1775. doi:10.1093/jn/nxy197 (PMID: 30383278)
This article is educational and not medical advice. See our medical disclaimer.